Breast cancer is the most common malignancy and the leading cause of cancer deaths in women worldwide. While specific genetic mutations have been linked to 5–10% of breast cancer cases, other environmental and epigenetic factors influence the development and progression of the cancer. Since unique mutations patterns have been observed in individual cancer samples, identification and characterization of the distinctive breast cancer molecular profile is needed to develop more effective target therapies. Until recently, identifying genetic cancer mutations via personalized DNA sequencing was impractical and expensive. The recent technological advancements in next-generation DNA sequencing, such as the semiconductor-based Ion Torrent sequencing platform, has made DNA sequencing cost and time effective with more reliable results. Using the Ion Torrent Ampliseq Cancer Panel, we sequenced 737 loci from 45 cancer-related genes to identify genetic mutations in 105 human breast cancer samples. The sequencing analysis revealed missense mutations in PIK3CA, and TP53 genes in the breast cancer samples of various histologic types. Thus, this study demonstrates the necessity of sequencing individual human cancers in order to develop personalized drugs or combination therapies to effectively target individual, breast cancer-specific mutations.
References
[1]
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, et al. (2013) GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. International Agency for Research on Cancer.
[2]
Jemal A (2010) Center MM, DeSantis C, Ward EM (2010) Global Patterns of Cancer Incidence and Mortality Rates and Trends. Cancer Epidemiology Biomarkers & Prevention 19: 1893–1907. doi: 10.1158/1055-9965.epi-10-0437
[3]
Etzioni R, Urban N, Ramsey S, McIntosh M, Schwartz S, et al. (2003) The case for early detection. Nat Rev Cancer 3: 243–252. doi: 10.1038/nrc1041
[4]
Blackburn GL, Wang KA (2007) Dietary fat reduction and breast cancer outcome: results from the Women’s Intervention Nutrition Study (WINS). Am J Clin Nutr 86: s878–881.
[5]
Chen WY, Colditz GA (2007) Risk factors and hormone-receptor status: epidemiology, risk-prediction models and treatment implications for breast cancer. Nat Clin Pract Oncol 4: 415–423. doi: 10.1038/ncponc0851
[6]
Brody JG, Rudel RA, Michels KB, Moysich KB, Bernstein L, et al. (2007) Environmental pollutants, diet, physical activity, body size, and breast cancer. Cancer 109: 2627–2634. doi: 10.1002/cncr.22656
[7]
Fackenthal JD, Olopade OI (2007) Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat Rev Cancer 7: 937–948. doi: 10.1038/nrc2054
[8]
Easton DF, Ford D, Bishop DT (1995) Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 56: 265–271.
[9]
Levin B, Lech D, Friedenson B (2012) Evidence that BRCA1- or BRCA2-associated cancers are not inevitable. Mol Med 18: 1327–1337.
[10]
Wooster R, Weber BL (2003) Breast and Ovarian Cancer. New England Journal of Medicine 348: 2339–2347. doi: 10.1056/nejmra012284
[11]
Easton DF (1999) How many more breast cancer predisposition genes are there? Breast Cancer Res 1: 14–17.
[12]
Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. (2000) Molecular portraits of human breast tumours. Nature 406: 747–752.
[13]
Hadd AG, Houghton J, Choudhary A, Sah S, Chen L, et al. (2013) Targeted, high-depth, next-generation sequencing of cancer genes in formalin-fixed, paraffin-embedded and fine-needle aspiration tumor specimens. J Mol Diagn 15: 234–247. doi: 10.1016/j.jmoldx.2012.11.006
[14]
Bader AG, Kang S, Vogt PK (2006) Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proceedings of the National Academy of Sciences of the United States of America 103: 1475–1479. doi: 10.1073/pnas.0510857103
[15]
Kang S, Bader AG, Zhao L, Vogt PK (2005) Mutated PI 3-Kinases: Cancer Targets on a Silver Platter. Cell Cycle 4: 571–574. doi: 10.4161/cc.4.4.1593
[16]
Zhao L, Vogt PK (2008) Class I PI3K in oncogenic cellular transformation. Oncogene 27: 5486–5496. doi: 10.1038/onc.2008.244
[17]
Faber AC, Corcoran RB, Ebi H, Sequist LV, Waltman BA, et al. (2011) BIM Expression in Treatment-Na？ve Cancers Predicts Responsiveness to Kinase Inhibitors. Cancer Discovery 1: 352–365. doi: 10.1158/2159-8290.cd-11-0106
[18]
Levine AJ (1997) p53, the Cellular Gatekeeper for Growth and Division. Cell 88: 323–331. doi: 10.1016/s0092-8674(00)81871-1
[19]
Langerod A, Zhao H, Borgan O, Nesland J, Bukholm I, et al. (2007) TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer. Breast Cancer Research 9: R30. doi: 10.1186/bcr1675
[20]
Roukos D, Ku CS (2012) Clinical Cancer Genome and Precision Medicine. Annals of Surgical Oncology 19: 3646–3650. doi: 10.1245/s10434-012-2542-9
[21]
Singh RR, Patel KP, Routbort MJ, Reddy NG, Barkoh BA, et al. (2013) Clinical Validation of a Next-Generation Sequencing Screen for Mutational Hotspots in 46 Cancer-Related Genes. The Journal of Molecular Diagnostics 15: 607–622. doi: 10.1016/j.jmoldx.2013.05.003
[22]
Beadling C, Neff TL, Heinrich MC, Rhodes K, Thornton M, et al. (2013) Combining Highly Multiplexed PCR with Semiconductor-Based Sequencing for Rapid Cancer Genotyping. The Journal of Molecular Diagnostics 15: 171–176. doi: 10.1016/j.jmoldx.2012.09.003
[23]
Pérez-Tenorio G, Alkhori L, Olsson B, Waltersson MA, Nordenskj？ld B, et al. (2007) PIK3CA Mutations and PTEN Loss Correlate with Similar Prognostic Factors and Are Not Mutually Exclusive in Breast Cancer. Clinical Cancer Research 13: 3577–3584. doi: 10.1158/1078-0432.ccr-06-1609
[24]
Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, et al. (2007) A Functional Genetic Approach Identifies the PI3K Pathway as a Major Determinant of Trastuzumab Resistance in Breast Cancer. Cancer cell 12: 395–402. doi: 10.1016/j.ccr.2007.08.030
[25]
Toi M, Iwata H, Fujiwara Y, Ito Y, Nakamura S, et al. (2009) Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies. Br J Cancer 101: 1676–1682.
[26]
Xu BH, Jiang ZF, Chua D, Shao ZM, Luo RC, et al. (2011) Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients. Chin J Cancer 30: 327–335. doi: 10.5732/cjc.010.10507
[27]
Alsner J, Yilmaz M, Guldberg P, Hansen LL, Overgaard J (2000) Heterogeneity in the Clinical Phenotype of TP53 Mutations in Breast Cancer Patients. Clinical Cancer Research 6: 3923–3931. doi: 10.1186/bcr109
[28]
Pharoah PDP, Day NE, Caldas C (1999) Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis. Br J Cancer 80: 1968–1973.
[29]
Bertucci F, Birnbaum D (2008) Reasons for breast cancer heterogeneity. Journal of Biology 7: 6. doi: 10.1186/jbiol67
[30]
Nielsen DL, Kümler I, Palshof JAE, Andersson M (2013) Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors. The Breast 22: 1–12. doi: 10.1016/j.breast.2012.09.008
[31]
Scaltriti M, Rojo F, Oca？a A, Anido J, Guzman M, et al. (2007) Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapies in Breast Cancer. Journal of the National Cancer Institute 99: 628–638. doi: 10.1093/jnci/djk134
[32]
Xia W, Husain I, Liu L, Bacus S, Saini S, et al. (2007) Lapatinib Antitumor Activity Is Not Dependent upon Phosphatase and Tensin Homologue Deleted on Chromosome 10 in ErbB2-Overexpressing Breast Cancers. Cancer Research 67: 1170–1175. doi: 10.1158/0008-5472.can-06-2101
[33]
Nakopoulou LL, Alexiadou A, Theodoropoulos GE, Lazaris AC, Tzonou A, et al. (1996) PROGNOSTIC SIGNIFICANCE OF THE CO-EXPRESSION OF p53 AND c-erbB-2 PROTEINS IN BREAST CANCER. The Journal of Pathology 179: 31–38. doi: 10.1002/(sici)1096-9896(199605)179:1<31::aid-path523>3.0.co;2-o
[34]
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, et al. (2001) Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2. New England Journal of Medicine 344: 783–792. doi: 10.1056/nejm200103153441101
[35]
Montemurro F, Valabrega G, Aglietta M (2007) Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity. Expert Opin Biol Ther 7: 257–268. doi: 10.1517/14712598.7.2.257
[36]
Obiorah I, Jordan VC (2011) Progress in endocrine approaches to the treatment and prevention of breast cancer. Maturitas 70: 315–321. doi: 10.1016/j.maturitas.2011.09.006
[37]
Fabian CJ (2007) The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer. International Journal of Clinical Practice 61: 2051–2063. doi: 10.1111/j.1742-1241.2007.01587.x
[38]
Lazzeroni M, DeCensi A (2013) Breast Cancer Prevention by Antihormones and Other Drugs: Where Do We Stand? Hematology/Oncology Clinics of North America 27: 657–672. doi: 10.1016/j.hoc.2013.05.009
[39]
Cauley J, Norton L, Lippman M, Eckert S, Krueger K, et al. (2001) Continued Breast Cancer Risk Reduction in Postmenopausal Women Treated with Raloxifene: 4-Year Results from the MORE Trial. Breast Cancer Research and Treatment 65: 125–134. doi: 10.1023/a:1006478317173
